Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 91

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 91
---
 include the following: 

•In October 2025, we announced the addition of two genes, F8 and FXN, to the Foresight Carrier Screen Universal Plus Panel.

•In September 2025, we announced a strategic collaboration with SOPHiA Genetics, Inc. to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.

•In September 2025, we announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual.

•Effective August 16, 2025, Benjamin R. Wheeler was appointed Chief Financial Officer. 

Results of Operations for the Three Months Ended September 30, 2025 and 2024

The results of operations for the three months ended September 30, 2025 and 2024 are discussed below.  

Revenue

The following table summarizes year-over-year revenue changes in our core product categories:

Three months ended September 30,% of Total Revenue(in millions)20252024Change20252024Hereditary Cancer$93.0 $90.5 $2.5 45%43%Tumor Profiling29.5 31.6 (2.1)14%15%Prenatal44.5 43.5 1.0 22%20%Pharmacogenomics38.7 47.7 (9.0)19%22%Total revenue$205.7 $213.3 $(7.6)100%100%

The following table summarizes volume changes in our core product categories:

Three months ended September 30,(in thousands)20252024% ChangeVolume:Hereditary Cancer82 74 11 %Tumor Profiling12 13 (8)%Prenatal155 162 (4)%Pharmacogenomics137 127 8 %Total386 376 3 %

Revenues decreased $7.6 million for the three months ended September 30, 2025 compared to the same period in the prior year primarily due to $8.6 million of revenue recognized during the three months ended September 30, 2024 for tests in which the performance obligation was met in a prior period. For the three months